Unflattening The Curve: Minimize The Impact To Patients Who Depend On Your Successful Clinical Trial

In this time of uncertainty caused by the COVID-19 pandemic, the importance of delivering new treatments to patients as quickly as possible has never been more vital.

Similar to how the response and immediate action to the “Flattening the Curve” movement in 2020 was executed to dramatically lessen the severity and impact of the pandemic on millions of lives, the actions and strategies implemented in today’s clinical studies will impact how patients in current trials will get their investigational treatments. Without a proactive and comprehensive strategy in place to manage clinical trials during the pandemic, consequences may be severe –especially for those that need the treatment the most.

While each study is unique, there are three critical areas to consider in managing clinical trials in the wake of the Coronavirus – and any future pandemics to come. Proper early response strategies can significantly save time in the development process, get treatments to market faster, and most importantly, ensure that patients have the greatest chance for continued access to treatment.